Why is this ASX 200 share charging 7% higher today?

This stock is making its shareholders smile on Tuesday. Let's find out why. The post Why is this ASX 200 share charging 7% higher today? appeared first on The Motley Fool Australia.
CURE

FDA Approves Pylarify TruVu to Expand Prostate Cancer Imaging

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Targeted Oncology

FDA OKs New Piflufolastat F 18 Formulation for Prostate Cancer Imaging

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Lantheus Holdings, Inc.: Lantheus Announces FDA Approval of PYLARIFY TruVu (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...
Bizcommunity on MSN

Vincent Pallotti Hospital enhances cancer care with new digital PET-CT scanner

The Life Vincent Pallotti Hospital in Cape Town has recently improved its cancer diagnostics by installing a digital PET-CT (positron emission tomography-computed tomography) scanner. This scanner, a ...

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
KFGO

US FDA approves Lantheus’ new prostate cancer imaging formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging ...